SCHEMBL5698940

SCHEMBL5698940

NC(=O)NOCC(O)CN1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ABCB1 P08183 10/20 0.49
ATM Q13315 2/20 0.49
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 1/20 0.47
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.45
HIF1A Q16665 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ACE2 Q9BYF1 1/20 0.44
MAPT P10636 1/20 0.44
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6745840 0.85 MEN1 (0.48) MEN1KMT2AABCB1ATMCYP2D6
SCHEMBL7526130 0.83 ABCB1 (0.49) MEN1KMT2AABCB1ATMCYP2D6
SCHEMBL7530991 0.81 ABCB1 (0.48) MEN1KMT2AABCB1ATMCYP2D6
SCHEMBL28123602 0.79 PKM (0.56) MEN1KMT2AABCB1ATMCYP2D6
SCHEMBL3076619 0.79 ALDH1A1 (0.48) MEN1KMT2AABCB1ATMCYP2D6
SCHEMBL3069255 0.78 ALDH1A1 (0.49) MEN1KMT2AABCB1ATMPKM
SCHEMBL3055428 0.78 ABCB1 (0.45) MEN1KMT2AABCB1ATMCYP2D6
SCHEMBL3067988 0.77 KMT2A (0.57) MEN1KMT2AABCB1ATMCYP2D6
SCHEMBL6631200 0.77 ABCB1 (0.44) MEN1KMT2AABCB1ATMCYP2D6
Hydrochloric Acid SCHEMBL8791052 0.77 ABCB1 (0.44) ABCB1CYP2D6CYP2C19HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966283-B1 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING DISEASES RESULTING FROM THE DAMAGING OF THE VASCULAR ENDOTHELIAL CELLS CYTRX CORP (US) 2006-06-14 EP claimed
EP-0966283-A2 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS BIOREX RT. (HU) 1999-12-29 EP claimed
WO-1998006400-A2 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS BIOREX KUTATÓ ÉS FEJLESZTO^' RT. (HU) 1998-02-19 WO claimed
EP-0966283-B1 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING DISEASES RESULTING FROM THE DAMAGING OF THE VASCULAR ENDOTHELIAL CELLS CYTRX CORP (US) 2006-06-14 EP disclosed
EP-0966283-A2 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS BIOREX RT. (HU) 1999-12-29 EP disclosed
WO-1998006400-A2 PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS BIOREX KUTATÓ ÉS FEJLESZTO^' RT. (HU) 1998-02-19 WO disclosed
EP-0801649-A2 HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF BIOREX KUTATO ES FEJLESZTÖ RT. (HU) 1997-10-22 EP disclosed
WO-1997016439-A1 HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF Biorex Kutató és Fejlesztó Rt. (HU) 1997-05-09 WO disclosed